Pharmaceutical

Ascentage Pharma raises $126m in first biotech IPO of 2025

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.

Jan 26, 2025 - 06:00
Ascentage Pharma raises $126m in first biotech IPO of 2025
The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood cancer.
Read the original article

Tags:

Previous Article

Mini-Organs in a Dish to Revolutionize Rare Disease Therapy

Next Article

Purdue and Sackler family agree to $7.4bn national opioid settlement

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CDC and social media: The new misinformation war

CDC and social media: The new misinformation war

Feb 7, 2024

Opinion: Why genetic testing should always be offered to children with neurodevelopmental differences

Opinion: Why genetic testing should always be offered t...

Apr 11, 2023

China’s NMPA accepts IND for SinoMab BioScience’s SM17 to treat asthma

China’s NMPA accepts IND for SinoMab BioScience’s SM17 ...

May 22, 2023